At Targeted Alpha Therapeutics (TalphaT), we imagine a future where advanced medical therapies are both feasible and within reach for all. Targeted radiation therapy is an attractive treatment for cancer, and radioactive material releasing alpha-particles is particularly effective at killing cancer cells while limiting harm to adjacent normal tissue.

TalphaT is developing a new and targeted radiation therapy for bladder cancer, consisting of repurposed FDA-approved therapeutic antibodies that bind cell surface receptors overexpressed in bladder cancer, labeled with the radioisotope Bismuth-213. For patients with stage 1 cancer, this new drug product is a guided missile that specifically targets bladder cancer cells, leading to improved patient outcomes for over 725,000 Americans living with bladder cancer.

In collaboration with our partner Niowave, Inc., we have developed a proprietary method for automatic generation of radioactive Bi-213 from an easily replenished source of another naturally occurring, long-lived radioisotope. This device reliably produces Bi-213 on-site, simplifying the manufacturing process, which affords radiopharmacists greater flexibility in administering doses to patients.

Founded in 2005, Niowave, Inc. is headquartered in Lansing, Michigan. Niowave is a trusted supplier of medical radioisotopes and a recognized global leader in superconducting electron linear accelerator technology and advanced radiochemistry. These core capabilities directly support the production of short-lived, high-value isotopes essential for targeted therapies. Through continuous innovation in accelerator design and radiochemistry processes, Niowave provides dependable, scalable isotope production that helps accelerate the fight against cancer. To learn more, visit the Niowave website.